Cipher Pharmaceuticals Inc
TSX:CPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hootech Inc
SZSE:301026
|
CN |
|
Aluminum Corporation of China Ltd
SSE:601600
|
CN |
|
Nexoptic Technology Corp
XTSX:NXO
|
CA |
Cipher Pharmaceuticals Inc
EPS (Diluted)
Cipher Pharmaceuticals Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
EPS (Diluted)
$0
|
CAGR 3-Years
21%
|
CAGR 5-Years
18%
|
CAGR 10-Years
19%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
EPS (Diluted)
CA$0
|
CAGR 3-Years
47%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
EPS (Diluted)
$0
|
CAGR 3-Years
64%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
EPS (Diluted)
-$1
|
CAGR 3-Years
6%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-6%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
EPS (Diluted)
CA$0
|
CAGR 3-Years
42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cipher Pharmaceuticals Inc
Glance View
Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.
See Also
What is Cipher Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
0.7
USD
Based on the financial report for Sep 30, 2025, Cipher Pharmaceuticals Inc's EPS (Diluted) amounts to 0.7 USD.
What is Cipher Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
19%
Over the last year, the EPS (Diluted) growth was 3%. The average annual EPS (Diluted) growth rates for Cipher Pharmaceuticals Inc have been 21% over the past three years , 18% over the past five years , and 19% over the past ten years .
